You are here

Insurance medicine national : The CLHIA publishes its recommendations


Susan Yellin

4 October 2018 11:30

Stephen Frank

L’Association canadienne des compagnies d’assurances de personnes (CLHIA) has developed a list of recommendations to protect and improve the insurance systems in place, to ensure insurance coverage for medicines for all and to ensure that medicines are affordable for consumers and taxpayers.

According to the CLHIA, the recommendations, included in a submission to the federal advisory Committee on a national pharmacare plan, can be implemented quickly by putting forward ” reform smart that build on the strengths of the current system “.

“The most important thing is that there is a pathway that takes what works well today and that will also help to achieve the strategic objectives defined by the council, which is to ensure that the conditions of access are not disrupted and to improve the financial situation of the insurance system drugs, said Stephen Frank, president and CEO of the CLHIA, in interview to the Newspaper of insurance. If it is done intelligently, it can be quick and Canada will be well served “.

The maintenance of private pension plans

According to the memorandum, any reform should ensure the maintenance of private health insurance plans. “Put them in peril will mean a delayed access to new innovative medicines, and more than 7.7 million Canadians would lose access to the medications they are taking at the present time. People suffering from depression, diabetes, cancer and pain issues would be most heavily affected. “

Maintain the current system of regimes, public and private-is a model that would also reduce costs overall and improve access, while efficiently using the taxpayers ‘ money, says the CLHIA.

The organization also suggests the establishment of a standard form of the national minimum covering chronic diseases, and scarce. The form would set a maximum for personal expenses, potentially based on revenue.

The CLHIA suggests that the government is working with industry to develop a model of risk-sharing for drugs with high costs, in order to ensure that all regions and all employers can offer the standard form minimum.

Cost of medication high

The CLHIA supports the reforms of the review Board the patented medicine prices (PMPRB), which regulates the maximum price that can be charged for a medicine in Canada. At the present time, the board establishes the cap by comparing the prices in Canada and seven other countries. “Canada has always tried to be the median of the seven countries,” said Mr. Frank.

However, the problem is that these other countries are experiencing the costs are the highest in the world. Ottawa is trying to introduce new reforms to help bring down the canadian prices much lower, said Frank.

The Canadian agreement to keep the private plans

Mr. Frank stated that the CLHIA has surveyed Canadians and 90% of them agree with the idea of adopting a reform to those who need it, without putting in danger the benefits they already have.

“The public believes that it is necessary to repair the system to help those who are left behind and reduce the costs, but not so as to compromise what already works,” says Stephen Frank.

The advisory committee will publish a report in June 2019, at which point the federal government will decide on the next steps to take.

Related posts

Leave a Comment